- Trial phase
- Phase 2
- Time to market
- At least several years away, if successful. The DPN Phase 2 data is expected in mid-2027, and Phase 3 trials would follow. No regulatory filings are imminent.
- Why 3/10
- VX-993 has no upcoming PDUFA or pivotal binary catalyst within the next 12 months; the next catalyst is the Phase 2 DPN topline readout expected in mid-2027, more than 6 months away. Even that readout would affect a small fraction of Vertex's value given its diversified pipeline of approved products (Trikafta, Alyftrek, Casgevy, Journavx) and its pending povetacicept PDUFA in November 2026.
The next catalyst is the Phase 2 DPN topline readout expected in mid-2027; a positive result could revive the program's prospects in chronic pain, while a negative readout would likely end it. For Vertex, this is one of many pipeline programs, but investors should watch upcoming quarterly updates for enrollment-completion confirmation.
Price Chart
Executive Summary
VX-993 is an oral NaV1.8 sodium channel blocker (pain signal inhibitor) from Vertex Pharmaceuticals, designed as a next-gen follow-up to Vertex's approved Journavx (suzetrigine). In August 2025, the drug failed its Phase 2 acute pain trial, missing the primary endpoint in a bunionectomy study, leading Vertex to discontinue acute pain development. However, a separate Phase 2 trial in diabetic peripheral neuropathy (DPN) is still recruiting. Vertex confirmed in its Q3 2026 earnings release (November 2, 2026) that enrollment in the DPN study remains on track to finish by year-end 2026, with results expected in mid-2027. At a large, diversified biotech like Vertex, VX-993 is a modest pipeline asset with no near-term binary catalyst.
How It Works
VX-993 blocks the NaV1.8 sodium channel on pain-sensing nerve cells in the peripheral nervous system. This channel acts like a relay station: when tissue is injured or damaged, pain signals travel through these channels toward the spinal cord and brain. By blocking the channel, VX-993 aims to prevent pain signals from reaching the brain, without the addictive potential of opioids.
Trial Status
A Phase 2 study in acute pain (bunionectomy) completed and failed to meet its primary endpoint in August 2025. A separate Phase 2 study in diabetic peripheral neuropathy (DPN) NCT06619860 is actively recruiting at 47 sites across 6 countries. Vertex expects enrollment to complete by end of 2026 with topline results in mid-2027.
The Two-Sided Case
Upcoming Catalysts
- Enrollment completion for Phase 2 DPN study expected by end of 2026
- Phase 2 DPN topline results expected mid-2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
VERTEX PHARMACEUTICALS INC / MA 8-K VRTX ·Originating report